[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648099":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":66,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":10,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Cryptosporidiosis Cohort",null,"Pediatric participants with diarrhea due to Cryptosporidium infection.",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":10},[23,37,48,56],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Novartis Investigative Site","RECRUITING","Kisumu","Nyanza","40100","Kenya","KE",{"type":32,"coordinates":33},"Point",[34,35],34.76171,-0.10221,{"lat":35,"lon":34},{"facility":24,"status":25,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":47,"contacts":10},"Kuantan","Pahang","25200","Malaysia","MY",{"type":32,"coordinates":44},[45,46],103.326,3.8077,{"lat":46,"lon":45},{"facility":24,"status":25,"city":49,"state":10,"zip":50,"country":41,"countryCode":42,"cosmosGeoPoint":51,"geoPoint":55,"contacts":10},"Kuala Lumpur","56000",{"type":32,"coordinates":52},[53,54],101.68653,3.1412,{"lat":54,"lon":53},{"facility":24,"status":25,"city":57,"state":10,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"Lusaka","10101","Zambia","ZM",{"type":32,"coordinates":62},[63,64],28.28713,-15.40669,{"lat":64,"lon":63},{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100648099","a-study-to-characterize-the-clinical-presentation-and-course-of-cryptosporidium-in-pediatric-participants-100648099",false,"NCT07716410","A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants","A Prospective Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants With Symptomatic Cryptosporidiosis in Endemic Countries","Inclusion criteria:\n\n* Age 6 months to 59 months with diarrhea according to the World Health Organization (WHO) criteria (≥3 loose stools daily for at least 2 days)\n* QuikChek™ and Stool microscopy positive for Cryptosporidium at screening\n* Acute (\\\u003C7 days), prolonged (lasting 7-13 days), persistent (lasting 14-28 days) or chronic (lasting \\>28 days) diarrheal illness (≥3 loose stools daily, as defined by WHO) at screening\n* Normal nutritional status, mildly-to-moderately acutely malnourished, or severely acutely malnourished according to WHO definitions (number of participants with severe acute malnutrition will be capped) at screening\n* Parent or primary caregiver is willing to provide informed consent and to comply with study procedures, including provision of whole stool samples at the scheduled time points and willing to be followed up to 21 days\n\nExclusion criteria:\n\n* Bloody diarrhea, defined as diarrhea with visible blood in stool as observed by the study team member performing the screening or reported by parent\u002Fprimary caregiver\n* Other morbidity requiring emergency medical care in an intensive care setting at the time of screening\n* Coincident non-enteric infection including upper or lower respiratory infection at screening\n* Any participant whose parent or primary caregiver is unwilling or unable to cooperate with study procedures, in the investigator's opinion\n* If the parent\u002Fprimary caregiver managing care of the patient has travel plans out of the study area that would preclude clinic or in-home study visits during the expected study follow-up period\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","6 Months","59 Months",{"count":79,"type":80},30,"ESTIMATED","OBSERVATIONAL","This study aims to characterize the pediatric cryptosporidiosis disease profile with respect to clinical presentation.",[84],"Cryptosporidiosis",[86,87,88,41,89],"Cryptosporidium","Observational","Africa","Pediatric Diarrhea","2026-07-15",{"date":92,"type":93},"2026-07-21","ACTUAL",{"date":95,"type":93},"2026-01-09",{"date":97,"type":80},"2027-05-19",{"name":14,"class":6},4]